Abhishek A. Chakraborty

Abhishek A. Chakraborty

Auto-generated profile, based on publicly available information

Abhishek A. Chakraborty

Case Comprehensive Cancer Center, Cleveland Clinic

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in Science
Verified
Journal Article
Closed access
PDF file
ACAbhishek A. Chakraborty
Abhishek A. Chakraborty
TLTuomas Laukka
Tuomas Laukka
MMMatti Myllykoski
Matti Myllykoski
ARAlison . Ringel
Alison . Ringel
MBMatthew A. Booker
Matthew A. Booker
WKWilliam G. Kaelin
William G. Kaelin
Oxygen sensing revisited: The cellular response to hypoxia (oxygen deficiency) is a contributing factor in many human diseases. Previous studies examining the way in which hypoxia alters gene expression have focused on oxygen-sensing enzymes that regulate the activity of a transcription factor called hypoxia-inducible factor (see the Perspective by Gallipoli and Huntly). Chakraborty et al. and Batie et al. now show that hypoxia can also affect gene expression through direct effects on chromatin regulators. Certain histone demethylases, such as KDM6A and KDM5A, were found to be direct sensors of oxygen. In cell-culture models, hypoxia diminished the activity of these enzymes and caused changes in the expression of genes that govern cell fate. Science , this issue p. 1217 , p. 1222 ; see also p. 1148

12 July 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ACAbhishek A. Chakraborty
Abhishek A. Chakraborty
ENEijiro Nakamura
Eijiro Nakamura
JQJun Qi
Jun Qi
ACAmanda Creech
Amanda Creech
JJJacob D. Jaffe
Jacob D. Jaffe
WKWilliam G. Kaelin
William G. Kaelin
Dysregulated H3K27 demethylase activity in pVHL-deficient cells increases dependence on the EZH1 H3K27 methyltransferase.


1 July 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TGTreg Grubb
Treg Grubb
SMSmruthi Maganti
Smruthi Maganti
JKJohn Michael Krill-Burger
John Michael Krill-Burger
CFCameron Fraser
Cameron Fraser
LSLaura Stransky
Laura Stransky
ACAbhishek A. Chakraborty
Abhishek A. Chakraborty
Purpose: Advanced/metastatic forms of clear-cell renal cell carcinomas (ccRCC) have limited therapeutic options. Genome-wide genetic screens have identified cellular dependencies in many cancers. Using the Broad Institute/Novartis combined short hairpin RNA (shRNA) dataset, and cross-validation with the CRISPR/Cas9 DepMap (21Q3) dataset, we sought therapeutically actionable dependencies in kidney lineage cancers. Experimental Design: We identified preferential genetic dependencies in kidney cancer cells versus other lineages. BCL2L1, which encodes the BCL-XL antiapoptotic protein, scored as the top actionable dependency. We validated this finding using genetic and pharmacologic tools in a panel of ccRCC cell lines. Select BCL-XL–dependent (versus independent) cell lines were then transcriptionally profiled to identify biomarkers and mechanistic drivers of BCL-XL dependence. Cell-based studies (in vitro and in vivo) and clinical validations were used to address physiologic relevance. Results: Inactivation of BCL-XL, but not BCL-2, led to fitness defects in renal cancer cells, and sensitized them to chemotherapeutics. Transcriptomic profiling identified a “BCL-XL dependency” signature, including an elevated mesenchymal gene signature. A mesenchymal state was both necessary and sufficient to confer increased BCL-XL dependence. The “BCL-XL dependency” signature was observed in approximately 30% of human ccRCCs, which were also associated with worse clinical outcomes. Finally, an orally bioavailable BCL-XL inhibitor, A-1331852, showed antitumor efficacy in vivo. Conclusions: Our studies uncovered an unexpected link between cell state and BCL-XL dependence in ccRCC. Therapeutic agents that specifically target BCL-XL are available. Our work justifies testing the utility of BCL-XL blockade to target, likely, a clinically aggressive subset of human kidney cancers. See related commentary by Wang et al., p. 4600


15 November 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SGShinjini Ganguly
Shinjini Ganguly
ZLZaeem Lone
Zaeem Lone
AMAndrew Muskara
Andrew Muskara
JIJarrell Imamura
Jarrell Imamura
AHAimalie Hardaway
Aimalie Hardaway
OMOmar Y. Mian
Omar Y. Mian
Half of all men with advanced prostate cancer (PCa) inherit at least 1 copy of an adrenal-permissive HSD3B1 (1245C) allele, which increases levels of 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) and promotes intracellular androgen biosynthesis. Germline inheritance of the adrenally permissive allele confers worse outcomes in men with advanced PCa. We investigated whether HSD3B1 (1245C) drives resistance to combined androgen deprivation and radiotherapy. Adrenally permissive 3βHSD1 enhanced resistance to radiotherapy in PCa cell lines and xenograft models engineered to mimic the human adrenal/gonadal axis during androgen deprivation. The allele-specific effects on radiosensitivity were dependent on availability of DHEA, the substrate for 3βHSD1. In lines expressing the HSD3B1 (1245C) allele, enhanced expression of DNA damage response (DDR) genes and more rapid DNA double-strand break (DSB) resolution were observed. A correlation between androgen receptor (AR) expression and increased DDR gene expression was confirmed in 680 radical prostatectomy specimens. Treatment with the nonsteroidal antiandrogen enzalutamide reversed the resistant phenotype of HSD3B1 (1245C) PCa in vitro and in vivo. In conclusion, 3βHSD1 promotes prostate cancer resistance to combined androgen deprivation and radiotherapy by upregulating DNA DSB repair. This work supports prospective validation of early combined androgen blockade for high-risk men harboring the HSD3B1 (1245C) allele.